
Shanghai Bao Pharmaceuticals Co., Ltd.
2659.HKHKSEHealthcareBiotechnology
最新データ
HK$15.73
−HK$0.36 · -2.24%
2659.HKの企業概要
日中の時刻はHKTです。市場データは遅延する場合があります。
企業プロフィール
会社ウェブサイトShanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodiumsulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.
- 業界
- Biotechnology
- セクター
- Healthcare
- 本社
- CN
- 最高経営責任者(CEO)
- Wang Zheng
- 上場以来
- 2025年12月10日
- 従業員
- 354
市場での位置
日中レンジ
現在 HK$15.73
52週レンジ
現在 HK$15.73
- 始値
- HK$16.12
- 前日終値
- HK$16.09
- 出来高
- 20.11万
- 0.08× 平均
- 平均出来高
- 266.66万
- 1日平均出来高
- 時価総額
- 24.02億 HKD
- ベータ
- 0.92
- 市場参照 1
- 50日平均
- HK$17.9348
- 平均以下(-12.29%)
- 200日平均
- HK$67.3497
- 平均以下(-76.64%)
2659.HKの同業他社
2659.HKを保有するETF
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Core MSCI Emerging Markets ETFIEMG42.9万0.00%1600.01億 USD0.09%$81.57+0.64%
iShares MSCI China Small-Cap ETFECNS2.77万0.04%6648.31万 USD0.59%$29.37+0.89%
State Street SPDR S&P China ETFGXC1.17万0.00%4.75億 USD0.59%$91.50+0.51%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM67700.00%17.41億 USD0.09%$87.80+0.55%
iShares Core 80/20 Aggressive Allocation ETFAOA770.690.00%32.86億 USD0.19%$99.01+0.49%
iShares Core 60/40 Balanced Allocation ETFAOR672.180.00%37.53億 USD0.20%$69.85+0.32%
iShares Core 40/60 Moderate Allocation ETFAOM216.470.00%17.81億 USD0.20%$49.77+0.18%
iShares Core 30/70 Conservative Allocation ETFAOK73.490.00%7.99億 USD0.20%$41.30+0.10%
iShares Core MSCI Emerging Markets ETFIEMG- 市場価値
- 42.9万
- 重さ
- 0.00%
- AUM
- 1600.01億 USD
- 経費率
- 0.09%
- 価格 / 1日
- $81.57+0.64%
iShares MSCI China Small-Cap ETFECNS- 市場価値
- 2.77万
- 重さ
- 0.04%
- AUM
- 6648.31万 USD
- 経費率
- 0.59%
- 価格 / 1日
- $29.37+0.89%
State Street SPDR S&P China ETFGXC- 市場価値
- 1.17万
- 重さ
- 0.00%
- AUM
- 4.75億 USD
- 経費率
- 0.59%
- 価格 / 1日
- $91.50+0.51%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM- 市場価値
- 6770
- 重さ
- 0.00%
- AUM
- 17.41億 USD
- 経費率
- 0.09%
- 価格 / 1日
- $87.80+0.55%
iShares Core 80/20 Aggressive Allocation ETFAOA- 市場価値
- 770.69
- 重さ
- 0.00%
- AUM
- 32.86億 USD
- 経費率
- 0.19%
- 価格 / 1日
- $99.01+0.49%
iShares Core 60/40 Balanced Allocation ETFAOR- 市場価値
- 672.18
- 重さ
- 0.00%
- AUM
- 37.53億 USD
- 経費率
- 0.20%
- 価格 / 1日
- $69.85+0.32%
iShares Core 40/60 Moderate Allocation ETFAOM- 市場価値
- 216.47
- 重さ
- 0.00%
- AUM
- 17.81億 USD
- 経費率
- 0.20%
- 価格 / 1日
- $49.77+0.18%
iShares Core 30/70 Conservative Allocation ETFAOK- 市場価値
- 73.49
- 重さ
- 0.00%
- AUM
- 7.99億 USD
- 経費率
- 0.20%
- 価格 / 1日
- $41.30+0.10%
GoAI で研究を続ける
GoAIで2659.HKを調査research.disclaimer





